The Zeno is now being FDA-reviewed for use in Neuregulin 1 fusion (NRG1+) non-small cell lung cancer (NSCLC) and NRG1+ pancreatic cancers (PDAC). This evidence concerns the gene NRG1 and non-small cell lung carcinoma.